Overview

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

Status:
Not yet recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

The whole study includes 2 parts. Both the SAD study and MAD study are randomized, double-blinded, and placebo-controlled studies, conducted in healthy subjects, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of CS0159. The SAD part also involves a pilot food effect (FE) study, designed to assess the food effect on single-dose PK profile in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Cascade Pharmaceuticals, Inc

Collaborator:

Covance